<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>FDA on k4i.com</title>
    <link>https://k4i.com/tags/fda/</link>
    <description>Recent content in FDA on k4i.com</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <lastBuildDate>Thu, 02 Apr 2026 00:00:00 +0000</lastBuildDate>
    <atom:link href="https://k4i.com/tags/fda/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Neural Implants: Where the Technology Actually Stands Right Now</title>
      <link>https://k4i.com/neural-implants-where-the-technology-actually-stands-right-now/</link>
      <pubDate>Thu, 02 Apr 2026 00:00:00 +0000</pubDate>
      <guid>https://k4i.com/neural-implants-where-the-technology-actually-stands-right-now/</guid>
      <description>&lt;p&gt;Fewer than 70 people worldwide have used a brain-computer interface that reads and decodes their neural signals. That number, drawn from the GAO&amp;rsquo;s April 2026 horizon report, is a useful corrective to the hype cycle that has surrounded this technology for years. The commercial narrative has run far ahead of clinical reality.&lt;/p&gt;&#xA;&lt;p&gt;The more mature category of neural implants — devices that send electrical signals into the brain to alter its activity — has a larger user base. More than 200,000 people have received deep brain stimulation devices for conditions like Parkinson&amp;rsquo;s disease and epilepsy. But these are strictly therapeutic, tightly regulated, and available only to patients who have not responded to other treatments. They are not precursors to consumer products. They are medical devices.&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
